Cleerly to Present Innovative Research on Age and Sex-Specific Coronary Artery Disease at AHA Scientific Sessions 2024
New Insights from AI-Quantitative Coronary CT (AI-QCT) Data to be Shared in Chicago, November 16-18, 2024
2 min read
Cleerly : February 2, 2022
Organization recognizes the most promising and innovative health startups in New York.
New York, February 2, 2022 -- Cleerly, the company creating a new standard of care for heart disease, announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to New York's healthcare ecosystem, has recognized the company on its NYC Digital Health 100, showcasing the most exciting and innovative health start-ups in New York.
"We are thrilled to be recognized on NYCHBL's Digital Health 100 among a list of impressive startups," said James K. Min, MD FACC, founder and CEO of Cleerly. "We continue to have a strong presence in New York City with our employee footprint, and working with prominent health care systems and research institutions as we strive to transform the way we evaluate heart disease."
Founded in 2017, Cleerly's digital care pathway leverages non-invasive coronary computed tomography (CT) angiography to perform comprehensive coronary artery phenotyping through artificial intelligence (AI)-enabled and FDA-cleared solutions. This technology is based on millions of annotated lab images used to build proprietary algorithms capable of quantifying and characterizing the presence, extent, severity and type of coronary artery disease and other cardiovascular disorders. Through this visibility and understanding of coronary artery disease, Cleerly is transforming the field of cardiovascular medicine by introducing a multidimensional approach to serve each and every stakeholder – from imaging physicians, to clinicians, to patients and payers.
"This year, the NYC Digital Health 100 is comprised of an incredibly diverse set of companies and leaders who are working to innovate and solve some of the most complex challenges across all facets of the healthcare ecosystem," said Bunny Ellerin, co-founder and CEO, NYCHBL. "We are delighted to recognize these companies and celebrate and support their growth in the New York area."
The NYC Digital Health 100 was released in conjunction with the NYCHBL Healthcare Innovation Report 2022, an in-depth look at the data, trends and insights that define the healthcare industry in NY. In 2021, 182 companies raised an historic high of $9.0B, a 150% increase from 2020 ($3.6B) and 87% of the investments went to start-ups in areas including virtual care, patient engagement and mental health. To review the report, please visit https://bit.ly/dh100-pr.
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared, value-based diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.
Download: JPG |
|
|
|
New Insights from AI-Quantitative Coronary CT (AI-QCT) Data to be Shared in Chicago, November 16-18, 2024
Part of the multicenter international CONFIRM2 Registry, the study found key metrics to predict cardiac events
After Five Years of Collaboration, Cleerly’s Innovative Technology Gains Permanent Recognition
Cleerly joins American Heart Association Center for Health Technology & Innovation Innovators’ NetworkAmerican Heart Association consortium advances...
New alliance combines Cleerly’s AI-enabled approach to identifying early signs of heart disease with Heartbeat Health’s nationwide footprint of...
Heart Health Innovator Cleerly Appoints Joseph Jasser, MD, as Chief of Value Based CareHire follows Cleerly's $223 million Series C and furthers...